Rosiglitazone

Overview

Rosiglitazone (trade name Avandia) is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5 billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5 million in 2012. The drug's patent expired in 2012.[1][2] WP

It was patented in 1987 and approved for medical use in 1999. Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits.[3][4][5] WP

Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the US. From November 2011 until November 2013, the US federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of a 2009 trial which failed to show increased heart attack risk.[6–9] WP

In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended because the benefits no longer outweighed the risks. It was withdrawn from the market in the UK, Spain and India in 2010, and in New Zealand and South Africa in 2011.[10–13] WP

Uses, dosage and effects

Medical uses

Rosiglitazone was approved for glycemic control in people with type 2 diabetes, as measured by glycated haemoglobin A1c (HbA1c) as a surrogate endpoint, similar to that of other oral antidiabetic drugs. The controversy over adverse effects has dramatically reduced the use of rosiglitazone.[14][15][16] WP

Published studies did not provide evidence that outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life are positively influenced by rosiglitazone.[14] WP

Risks and side effects

Heart failure

One of the safety concerns identified before approval was fluid retention. Moreover, the combination of rosiglitazone with insulin resulted in a higher rate of congestive heart failure. In Europe there were contraindications for use in heart failure and combination with insulin.[17] WP

A meta analysis of all trials from 2010 and 2019 confirmed a higher risk of heart failure and a double risk when rosiglitazone was administered as add-on therapy to insulin. Two meta-analyses of real life cohort studies found a higher risk of heart failure compared to pioglitazone. There were 649 excess cases of heart failure every 100,000 patients who received rosiglitazone rather than pioglitazone.[4][18][19][20] WP

Heart attacks

The relative risk of ischemic cardiac events seen in pre-approval trials of rosiglitazone was similar to that of comparable drugs, but there was increased LDL cholesterol, LDL/HDL cholesterol ratio, triglycerides and weight.[21][22] WP

In 2005, at the insistence of the World Health Organization, GSK performed a meta-analysis of all 37 trials involving use of rosiglitazone, finding a hazard ratio of 1.29 (0.99 to 1.89). In 2006 the GSK updated the analysis, now including 42 trials and showing a hazard ratio of 1.31 (1.01 to 1.70). A large observational study comparing patients treated with rosiglitizone with patients treated with other diabetes therapies was performed at the same time and found a relative risk of 0.93 (95% C.I. 0.8 to 1.1) for those treated with rosiglitazone. The information was passed to the FDA and posted on the company website, but not otherwise published. GSK provided these analyses to the FDA, but neither the company nor the FDA warned prescribers or patients of the hazard. According to the FDA, the Agency did not issue a safety bulletin because the results of the meta analysis conflicted with those of the observational study and with the results of the ADOPT trial.[23][24] WP

A meta-analysis in May 2007 reported the use of rosiglitazone was associated with a 1.4 fold increased risk of heart attack and a numerically higher (but non-significant) increase in risk of death from all cardiovascular diseases against control. It contained 42 trials of which 27 were unpublished. Another meta analysis of 4 trials with follow-up longer than 1 year found similar results. Nissen's meta analysis was criticized in a 2007 article by George Diamond et al. in the Annals of Internal Medicine. The authors concluded that Nissens' analysis had excluded trials with important data on the cardiovascular profile of rosiglitazone, had inappropriately combined trials of greatly differing design, and had inappropriately excluded trials with no cardiovascular events. The authors concluded that no firm conclusion could be drawn regarding whether rosiglitazone increased or decreased cardiovascular risk. Investigators from the Cochrane Collaboration published a meta-analysis of their own on the use of rosiglitazone in Type II diabetes, concluding there was not sufficient evidence to show any health benefit for rosiglitazone. Noting the recent publication by Nissen, they repeated their meta analysis including only the trials included in the Nissen study that dealt with Type II diabetics. (The Nissen study included some trials in people with other disorders.) They did not find a statistically significant increase in cardiovascular events, but noted that all of the cardiovascular endpoints they analyzed showed a non-significant trend toward worse outcomes in the rosiglitazone arms.[1][14][25][26] WP

In July 2007 the FDA held a joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. FDA scientist Joy Mele presented a meta analysis examining the cardiovascular risk of rosiglitazone in completed clinical trials. The study found an overall 1.4 fold increase in risk of cardiovascular ischemic events relative to the control arms. The results were heterogenous, with clear evidence of increased risk relative to placebo but not relative to other diabetes treatments and higher risk associated with combinations of rosiglitazone with insulin or metformin. Based on the 1.4 fold increased risk relative to control groups, FDA scientist David Graham presented an analysis suggesting that rosiglitazone had caused 83,000 excess heart attacks between 1999 and 2007. The advisory panel voted 20: 3 that the evidence available indicated that rosiglitazone increased the risk of cardiovascular events and 22: 1 that the overall risk:benefit ratio of rosiglitazone justified its continued marketing in the United States. The FDA placed restrictions on the drug, including adding a boxed warning about heart attacks, but did not withdraw it.[27–30] WP

In 2000 a study to address the concerns regarding cardiovascular safety was requested by the European Medicines Agency (EMA). GSK agreed to perform post-marketing a long-term cardiovascular morbidity/mortality study in patients on rosiglitazone in combination with a sulfonylurea or metformin: the RECORD study. The results as published in 2009 showed that rosiglitazone was non-inferior to treatment with metformin or a sulfonylurea with respect to the rate of cardiovascular events and cardiovascular death. European regulators concluded that due in part to design limitations, the results neither proved nor eliminated concerns of excess cardiovascular risk.[17] WP

In February 2010, the FDA's associate director of drug safety, recommended rosiglitazone be taken off the market. In June 2010, they published a retrospective study comparing roziglitazone to pioglitazone, the other thiazolidinedione marketed in the United States and concluded rosiglitazone was associated with "an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older". The number needed to harm with roziglitazone was sixty. Graham argued rosiglitazone caused 500 more heart attacks and 300 more heart failures than its main competitor.[31] WP

Two meta analyses released in 2010, one incorporating 56 trials and a second incorporating 164 trials reached conflicting conclusions. Nissen et al. found again an increased risk for heart infarction against control, but no increased risk for cardiovascular death. Mannucci et al. found no statistically significant increase in cardiac events but a significant increase in heart failure. A 2011 drug class review found an increased risk of cardiovascular adverse events.[18][32][33] WP

A meta-analysis of 16 observational studies released in March, 2011, compared rosiglitazone to pioglitazone, finding support for greater cardiovascular safety for pioglitazone. The meta-analysis involved 810 000 patients taking rosiglitazone or pioglitazone. The study suggests 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone. This was confirmed by another meta-analysis involving 945 286 patients in 8 retrospective cohort studies, most in the US.[4][20][34] WP

In 2012, the U.S. Justice Department announced GlaxoSmithKline had agreed to plead guilty and pay a $3 billion fine, in part for withholding the results of two studies of the cardiovascular safety of Avandia between 2001 and 2007.[35] WP

Death

There was no difference in all cause and vascular death in a meta-analysis of 4 trials against controls. Two meta-analyses of cohort studies found excess deaths against pioglitazone.[4][20][25][33] WP

Stroke

A retrospective observational study performed using Medicare data found that patients treated with rosiglitazone had a 27% higher risk of stroke compared to those treated with pioglitazone.[31] WP

Bone fractures

GlaxoSmithKline reported a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. The information was based on data from the ADOPT trial. The same increase has been found with pioglitazone (Actos), another thiazolidinedione.[36][37] WP

A meta-analysis of 10 RCTs, involving 13,715 patients and including both rosiglitazone- and pioglitazone-treated patients, showed an overall 45% increased risk of fracture with thiazolidone use compared with placebo or active comparator. It doubled the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.[38] WP

Hypoglycaemia

The risk of hypoglycaemia is reduced with thiazolidinediones when compared with sulfonylureas; the risk is similar to the risk with metformin (high strength of evidence).[33] WP

Weight gain

Both thiazolidinediones cause a similar degree of weight gain to that caused by sulfonylureas (moderate strength of evidence).[33] WP

Eye damage

Both rosiglitazone and pioglitazone have been suspected of causing macular edema, which damages the retina of the eye and causes partial blindness. Blindness is also a possible effect of diabetes, which rosiglitazone is intended to treat. One report documented several occurrences and recommended discontinuation at the first sign of vision problems. A retrospective cohort study showed an association between the use of thiazolidinediones and the incidence of diabetic macular edema (DME). Both use was associated with a 2,3 higher risk at 1 year and at 10 year follow-up, rising to 3 if associated with insulin.[33][39] WP

Hepatotoxicity

Moderate to severe acute hepatitis has occurred in several adults who had been taking the drug at the recommended dose for two to four weeks. Plasma rosiglitazone concentrations may be increased in people with existing liver problems.[40] WP

Contraindications

Both rosiglitazone and pioglitazone are contraindicated in people with NYHA Class III and IV heart failure. They are not recommended for use in heart failure.[41] WP

In Europe, rosiglitazone was contraindicated for heart failure or history of heart failure with regard to all NYHA stages, for combined use with insulin and for acute coronary syndrome. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market.[10][11][17] WP

Pharmacology

Pharmacology

Rosiglitazone is a member of the thiazolidinedione class of drugs. Thiazolidinediones act as insulin sensitizers. They reduce glucose, fatty acid, and insulin blood concentrations. They work by binding to the peroxisome proliferator-activated receptors (PPARs). PPARs are transcription factors that reside in the nucleus and become activated by ligands such as thiazolidinediones. Thiazolidinediones enter the cell, bind to the nuclear receptors, and alter the expression of genes. The several PPARs include PPARα, PPARβ/δ, and PPARγ. Thiazolidinediones bind to PPARγ. WP

PPARs are expressed in fat cells, cells of the liver, muscle, heart, and inner wall (endothelium) and smooth muscle of blood vessels. PPARγ is expressed mainly in fat tissue, where it regulates genes involved in fat cell (adipocyte) differentiation, fatty acid uptake and storage, and glucose uptake. It is also found in pancreatic beta cells, vascular endothelium, and macrophages Rosiglitazone is a selective ligand of PPARγ and has no PPARα-binding action. Other drugs bind to PPARα.[42] WP

Rosiglitazone also appears to have an anti-inflammatory effect in addition to its effect on insulin resistance. Nuclear factor kappa-B (NF-κB), a signaling molecule, stimulates the inflammatory pathways. NF-κB inhibitor (IκB) downregulates the inflammatory pathways. When patients take rosiglitazone, NF-κB levels fall and IκB levels increase.[43] WP

Research

Research

Rosiglitazone was thought to be able to benefit patients with Alzheimer's disease who do not express the ApoE4 allele, but the phase III trial designed to test this showed that rosiglitazone was ineffective in all patients, including ApoE4-negative patients.[44][45] WP

Rosiglitazone may also treat mild to moderate ulcerative colitis, due to its anti-inflammatory properties as a PPAR ligand.[46] WP

Rosiglitazone has been investigated as an agent that may expedite body fat redistribution into a more feminine shape in trans women who have had little fat redistribution from hormone replacement therapy, due to thiozolidinediones' effects on body fat metabolism.[47] WP

History

History

Rosiglitazone was approved by the US FDA in 1999 and by the EMA in 2000; the EMA however required two postmarketing studies on longterm adverse effects, one for chronic heart failure and the other for cardiovascular effects.[10] WP

Legal status

Sales

US sales of the drug were of $2.2 billion in 2006. Sales in 2Q 2007 down 22% compared to 2006. 4Q 2007 sales down to $252 million.[48][49][50] WP

Though sales have gone down since 2007 due to safety concerns, Avandia sales for 2009 totalled $1.2 billion worldwide.[51] WP

Lawsuits

According to analysts from UBS, 13,000 suits had been filed by March 2010. Included among those suing: Santa Clara County, California, which claims to have spent $2 million on rosiglitazone between 1999 and 2007 at its public hospital and is asking for "triple damages". In May 2010, GlaxoSmithKline (GSK) reached settlement agreements for some of the cases against the company, agreeing to pay $60 million to resolve 700 suits. In July 2010, GSK reached settlement agreements to close another 10,000 of the lawsuits against it, agreeing to pay about $460 million to settle these suits.[52–57] WP

In 2012, the U.S. Justice Department announced GlaxoSmithKline had agreed to plead guilty and pay a $3 billion fine, in part for withholding the results of two studies of the cardiovascular safety of Avandia between 2001 and 2007. The settlement stems from claims made by four employees of GlaxoSmithKline, including a former senior marketing development manager for the company and a regional vice president, who tipped off the government about a range of improper practices from the late 1990s to the mid-2000s.[35] WP

United states investigations

GlaxoSmithKline was being investigated by the FDA and the US Congress regarding Avandia. WP

Senators Democrat Max Baucus and Republican Charles Grassley filed a report urging GSK to withdraw Avandia in 2008 due to the side effects. The report noted the drug caused 500 avoidable heart attacks a month, and Glaxo officials sought to intimidate doctors who criticized the drug. It also said GSK continued to sell and promote the drug despite knowing the increased risk of heart attacks and stroke.[58] WP

The Senate Finance Committee, in a panel investigation, revealed emails from GSK company officials that suggest the company downplayed scientific findings about safety risks dating back to 2000. It was also alleged by the committee that the company initiated a "ghostwriting campaign", whereby GSK sought outside companies to write positive articles about Avandia to submit to medical journals. GSK defended itself by presenting data that its own tests found Avandia to be safe, although an FDA staff report showed the conclusions were flawed.[59][60] WP

On July 14, 2010, after two days of extensive deliberations, the FDA panel investigating Avandia came to a mixed vote. Twelve members of the panel voted to take the drug off the market, 17 recommended to leave it on but with a more revised warning label, and three voted to keep it on the market with the current warning label. The panel has come to some controversy, however; on July 20, 2010, one of the panelists was discovered to have been a paid speaker for GlaxoSmithKline, arousing questions of a conflict of interest. This panel member was one of the three who voted to keep Avandia on the market with no additional warning labels.[61–64] WP

In 2011 the FDA has decided on revising its prescribing information and medication guides for all rosilitazone containing medicines. The US label for rosiglitazone (Avandia, GlaxoSmithKline) and all rosiglitazone-containing medications (Avandamet and Avandaryl) now include the additional safety information and restrictions. The revised labels restrict use to patients already taking a rosiglitazone-containing medicine or to new patients who are unable to achieve adequate glycemic control on other diabetes medications and to those, who in consultation with their healthcare provider, have decided not to take Actos (pioglitazone) or other pioglitazone-containing medicines for medical reasons.[65][66][67] WP

In June 2013 an FDA Advisory Committee reviewed all available data, including a re-adjudicated RECORD trial, found no evidence of increased cardiovascular risk with Avandia, and voted to remove the restrictions on Avandia marketing in the United States. In November 2013, the US FDA removed these marketing restrictions on the product. Under the FDA's instruction, Avandia's maker, GlaxoSmithKline, had funded the Duke Clinical Research Institute to re-analyze the raw data from the study. At the 2010 panel, three panelists voted that the existing warnings were good enough; two were back in 2013. Seven voted to make those warnings more onerous, and five of them returned. But of the 10 who voted to restrict Avandia's use, only four returned. And of the 12 who voted in 2010 to withdraw Avandia from the market, only three came back.[68][69] WP

European investigations

In 2000 a study to address the concerns regarding cardiovascular safety was requested by the EMA, and the makers agreed to perform post-marketing a long-term cardiovascular morbidity/mortality study in patients on rosiglitazone in combination with a sulfonylurea or metformin: the RECORD study. The results as published in 2009 showed non-inferiority with regard to cardiovascular events and cardiovascular death when the treatment with rosiglitazone was compared with metformin or a sulfonylurea. For myocardial infarction, there was a non-statistically significant increase in risk. In their assessment, the European regulators acknowledged weaknesses of the study, such as an unexpectedly low rate of cardiovascular events and the open-label design, which may lead to reporting bias. They found that the results were inconclusive. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market.[10][11][17] WP

According to a probe by the British Medical Journal in September 2010, the United Kingdom's Commission on Human Medicines recommended to the Medicines and Healthcare Products Regulatory Agency (MHRA) back in July 2010, to withdraw Avandia sale because its "risks outweigh its benefits". Additionally, the probe revealed that in 2000, members of the European panel in charge of reviewing Avandia prior to its approval had concerns about the long-term risks of the drug.[70][71] WP

New zealand

Rosiglitazone was withdrawn from the New Zealand market April 2011 because Medsafe concluded the suspected cardiovascular risks of the medicine for patients with type 2 diabetes outweigh its benefits.[72] WP

South africa

A notice issued by the Medicines Control Council of South Africa on July 5, 2011, stated that it had resolved on July 3, 2011, to withdraw all rosiglitazone-containing medicines from the South African market due to safety risks. It disallowed all new prescriptions of Avandia.[73] WP

Controversy and response

Following the reports in 2007 that Avandia can significantly increase the risk of heart attacks, the drug has been controversial. A 2010 article in Time uses the Avandia case as evidence of a broken FDA regulatory system that "may prove criminal as well as fatal". It details the disclosure failures, adding, "Congressional reports revealed that GSK sat on early evidence of the heart risks of its drug, and that the FDA knew of the dangers months before it informed the public." It reports, "the FDA is investigating whether GSK broke the law by failing to fully inform the agency of Avandia's heart risks", according to deputy FDA commissioner Dr. Joshua Sharfstein. GSK threatened academics who reported adverse research results, and received multiple warning letters from the FDA for deceptive marketing and failure to report clinical data. The maker of the drug, GlaxoSmithKline, has dealt with serious backlash against the company for the drug's controversy. Sales on the drug dropped significantly after the story first broke in 2007, dropping from $2.5 billion in 2006 to less than $408 million in 2009 in the US.[74][75][76] WP

In response to the rise in risk of heart attacks, the Indian government ordered GSK to suspend its research study, called TIDE, in 2010. The FDA also halted the TIDE study in the United States.[77][78][79] WP

Three doctors' groups, the Endocrine Society, the American Diabetes Association and the American Association of Clinical Endocrinologists, urged patients to continue to take the drug as it would be much worse to stop all treatment, despite any associated risk, but that patients could consult their doctors and begin a switch to a different drug if they or their doctors find concern. The American Heart Association said in a statement in June 2010: "...the reports deserves serious consideration, and patients with diabetes who are 65 years of age or older and being treated with rosiglitazone should discuss the findings with their prescribing physician....". "For patients with diabetes, the most serious consequences are heart disease and stroke, and the risk of suffering from them is significantly increased when diabetes is present. As in most situations, patients should not change or stop medications without consulting their healthcare provider."[80–84] WP

Chemistry

Formula

C18H19N3O3S PC

CAS number

122320-73-4 PC

Molar mass (g/mol)

357.4 PC

IUPAC name (computed by PubChem)

5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione PC

SMILES

CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 PC

InChIKey

YASAKCUCGLMORW-UHFFFAOYSA-N PC

PubChem CID

77999

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine. June 2007. doi:10.1056/NEJMoa072761 · PMID 17517853
2. Other Novel compounds
3. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
4. Journal / agency Chen X, Yang L, Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chinese Medical Journal. December 2012. PMID 23217404
5. Other Glaxo Withheld Avandia Study, Ex-Regulator Said to Testify
6. Other Harris G. Controversial Diabetes Drug Harms Heart, U.S. Concludes. February 19, 2010
7. Other Most Popular E-mail Newsletter. 2011-05-24
8. Other Glaxo's Avandia Cleared From Sales Restrictions by FDA
9. Journal / agency U.S. Food and Drug Administration. FDA requires removal of certain restrictions on the diabetes drug Avandia. November 25, 2013
10. Journal / agency European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. 2018-09-17
11. Other Call to 'suspend' diabetes drug. 2010-09-23
12. Other Drugs banned in India
13. Other Diabetes drug withdrawn. 17 February 2011
14. Journal / agency Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews. July 2007. doi:10.1002/14651858.CD006063.pub2 · PMID 17636824 · PMC7389529
15. Journal / agency Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Archives of Internal Medicine. October 2008. doi:10.1001/archinte.168.19.2070 · PMID 18955635 · PMC2765722
16. Journal / agency Ajjan RA, Grant PJ. The cardiovascular safety of rosiglitazone. Expert Opinion on Drug Safety. July 2008. doi:10.1517/14740338.7.4.367 · PMID 18613801
17. Journal / agency Blind E, Dunder K, de Graeff PA, Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia. February 2011. doi:10.1007/s00125-010-1992-5 · PMID 21153629
18. Journal / agency Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. International Journal of Cardiology. August 2010. doi:10.1016/j.ijcard.2009.01.064 · PMID 19328563
19. Journal / agency Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. February 2020. doi:10.1136/bmj.l7078 · PMID 32024657 · PMC7190063
20. Journal / agency Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. March 2011. doi:10.1136/bmj.d1309 · PMID 21415101 · PMC3230110
21. Journal / agency Nissen S. Rosiglitazone a critical overview. Presentation to FDA Advisory Committee
22. Journal / agency Medical Officer's Review of New Drug Application 21-071: Rosiglitazone (Avandia). April 19, 1999
23. Journal / agency Nissen SE. Rosiglitazone: a case of regulatory hubris. BMJ. December 2013. doi:10.1136/bmj.f7428 · PMID 24335808
24. Journal / agency Safety of Rosiglitazone Maleate (Avandia)
25. Journal / agency Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. September 2007. doi:10.1001/jama.298.10.1189 · PMID 17848653
26. Journal / agency Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine. October 2007. doi:10.7326/0003-4819-147-8-200710160-00182 · PMID 17679700
27. Journal / agency Dockets
28. Other Staff report on GlaxoSmithKline and the diabetes drug Avandia. January 2010
29. Journal / agency Graham. Assessment of the cardiovascular risks and health benefits of rosiglitazone. 30 July 2007
30. Journal / agency FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia. Agency says drug to remain on market, while safety assessment continues. 14 November 2007
31. Journal / agency Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. July 2010. doi:10.1001/jama.2010.920 · PMID 20584880
32. Journal / agency Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine. July 2010. doi:10.1001/archinternmed.2010.207 · PMID 20656674
33. Journal / agency Jonas D, Van Scoyoc E, Gerrald K, Wines R, Amick H, Triplette M, Runge T. Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations Final Original Report Drug Class Reviews. 2011. PMID 21595121
34. Other Hughes S. More damning data on rosiglitazone. 27 March 2011
35. Other Thomas K, Schmidt MS. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. July 2, 2012
36. Journal / agency Clinical Trial Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with Avandia (rosiglitazone maleate) Tablets for Type 2 Diabetes Mellitus
37. Journal / agency Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine. December 2006. doi:10.1056/NEJMoa066224 · PMID 17145742
38. Journal / agency Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. January 2009. doi:10.1503/cmaj.080486 · PMID 19073651 · PMC2612065
39. Journal / agency Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ. February 2006. doi:10.1503/cmaj.060074 · PMID 16467508 · PMC1389823
40. Other R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1399-1400
41. Journal / agency rosiglitazone
42. Journal / agency Yki-Järvinen H. Thiazolidinediones. The New England Journal of Medicine. September 2004. doi:10.1056/NEJMra041001 · PMID 15356308
43. Journal / agency Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. The Journal of Clinical Endocrinology and Metabolism. June 2004. doi:10.1210/jc.2003-032103 · PMID 15181049
44. Journal / agency Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. The Pharmacogenomics Journal. 2006. doi:10.1038/sj.tpj.6500369 · PMID 16446752
45. Journal / agency Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders. 2010. doi:10.1159/000318845 · PMID 20733306 · PMC3214882
46. Journal / agency Lewis JD. Will 2008 mark the start of a new clinical trial era in gastroenterology?. Gastroenterology. May 2008. doi:10.1053/j.gastro.2008.03.030 · PMID 18471502
47. Journal / agency Malik I, Barrett J, Seal L. Thiazolindinediones are useful in achieving female type fat distribution in male to female transsexuals. Endocrine Abstracts. March 2009
48. Other FDA toughens Avandia warnings. 2007-11-14
49. Other Rubin R. FDA panels to weigh Avandia heart risks. 2007-07-26
50. Other Glaxo Fourth-Quarter Profit Fell 10% on Avandia Sales (Update6). 2008-02-07
51. Other Ranii D. Avandia fallout could hit Triangle. 2010-02-23
52. Other Ranii D. Avandia could cost GSK billions. 2010-03-05
53. Other California county sues Glaxo over diabetes drug. 2010-03-01
54. Other Feeley J, Kelley T. Glaxo Said to Pay About $60 Million in First Avandia Heart-Risk Settlement. 2010-05-11
55. Other Feeley J, Kelley T. Glaxo Said to Pay $460 Million to Settle Avandia Damage Suits. 2010-07-13
56. Other Dawber A. GSK 'settles Avandia claims' on first day of safety hearing. 2010-07-14
57. Other GSK settles bulk of Avandia suits for $460M. 14 July 2010
58. Other Interactive: Timeline: The story of Avandia | Need to Know. 16 July 2010
59. Other Avandia's Fate May be Sealed Today
60. Other Avandia Safety Questioned Again
61. Other 12 panel members recommend Avandia withdrawal. 14 July 2010
62. Other What is the meaning of the Avandia vote?. 14 July 2010
63. Other Mundy A. Panelist Who Backed Avandia Gets Fees From Glaxo. 2010-07-20
64. Other Gallagher J. Report: Avandia panelist paid by GSK. 2010-07-20
65. Journal / agency Ross JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND. State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. Health Affairs. January 2012. doi:10.1377/hlthaff.2011.1068 · PMID 22232110 · PMC3319744
66. Other O'Riordan M. New rosiglitazone label includes restrictions on use
67. Other GSK revises US Avandia label to include new restrictions on use
68. Journal / agency Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication – Removal of Some Prescribing and Dispensing Restrictions
69. Other Herper M. Avandia Vote Ends An Era Of Drug Safety Scandals. 2013-06-06
70. Other Douglas J. U.K. Medical Journal Questions Avandia License. 2010-09-06
71. Other U.K. watchdogs vote for Avandia withdrawal. 7 September 2010
72. Other Diabetes drug to be withdrawn over heart risk fears. Feb 17, 2011
73. Other Withdrawal of rosiglitazone-containing medicines from SA market
74. Other After Avandia: Does the FDA Have a Drug Problem?. Aug 12, 2010
75. Other Will Avandia Be Yanked Off the Market?
76. Other Exclusive: Takeda launches Actos DTC campaign today. 2010-07-15
77. Other Silverman E. An Undisclosed Conflict On The FDA Avandia Panel?. 2010-07-20
78. Other Avandia Drug Trials Shut Down In India. 2010-07-14
79. Other FDA Orders Glaxo to Stop an Avandia Trial
80. Other Don't dump Avandia, diabetes groups urge patients. 2010-07-15
81. Other Maugh II TH. Patients taking Avandia should keep on doing so, doctor groups say. 2010-07-15
82. Other Katz N. Avandia News: What You Need to Know. 2010-07-16
83. Other Booster Shots. 2010-06-29
84. Other American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.